Clinical Trial Update: A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of a three-dose MRKAd5 (Clade B) HIV vaccine (V520-018) in healthy adults has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MRKAd5 (Clade B) HIV vaccine (MRKAd5 (Clade B) vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1, HIV Infections | Phase 1 | Status: COMPLETED